The U.S. Food and Drug Administration (FDA) has granted marketing authorization for the Stelo Glucose Biosensor System, marking the first time the agency has cleared an over-the-counter (OTC) continuous glucose monitor (CGM) specifically for children as young as two years old. According to the official agency announcement released in late 2024, the device is intended for individuals who do not use insulin, providing a new option for monitoring glucose levels without the requirement of a prescription.
As a physician, I have closely followed the evolution of diabetes management technology. The expansion of this wearable sensor to younger populations represents a shift in how families might monitor metabolic health outside of clinical settings. The device, manufactured by Dexcom Inc., operates by measuring glucose levels in interstitial fluid through a small sensor worn on the back of the upper arm, transmitting data directly to a compatible smartphone application.
Understanding the Stelo Glucose Biosensor System
The Stelo system is categorized by the FDA as an integrated continuous glucose monitor (iCGM). Unlike prescription-based systems designed for intensive diabetes management—such as those used by patients requiring insulin therapy—the Stelo is designed for individuals who do not use insulin and are at least two years of age. The FDA’s De Novo classification confirms that the device meets safety and performance standards for its intended use, which includes providing real-time glucose trends and alerts for users.
The system is not intended to replace the clinical judgment of a pediatrician or endocrinologist. It is designed to provide users and caregivers with insights into how different foods, physical activities, and sleep patterns influence glucose levels. Because it is an OTC product, it does not require a doctor’s order, though the FDA emphasizes that users should not make medical decisions based on the device’s readings without consulting a healthcare professional.
Clinical Considerations for Pediatric Use
The transition of CGM technology into the OTC market for children requires careful interpretation of data. While the device offers a non-invasive way to track glucose, it does not diagnose diabetes or other metabolic conditions. According to the Centers for Disease Control and Prevention (CDC), continuous glucose monitoring is most effective when integrated into a broader health management plan. For children, the data provided by a CGM should be viewed as a tool for health literacy rather than a diagnostic substitute.
Parents and guardians should note that the device’s software provides alerts when glucose levels fall outside of a set range, but these alerts are not intended to replace standard clinical testing for conditions like hypoglycemia or hyperglycemia. The FDA mandate specifies that the device should not be used by individuals who require insulin, as they need more rigorous monitoring protocols typically managed by a prescription-based device.
Technological Impact on Public Health
The availability of an OTC monitor for children is part of a broader trend in medical innovation where diagnostic tools are becoming increasingly accessible. By removing the prescription barrier, the FDA aims to empower families to observe physiological responses to lifestyle factors in real-time. This aligns with a growing emphasis on preventative health and patient-centered monitoring.
However, the medical community maintains that technology must be balanced with professional oversight. The American Diabetes Association notes that while wearable technology can improve engagement, the interpretation of trends—especially in developing children—remains a task best performed in collaboration with a primary care provider. Families interested in utilizing this device should verify compatibility with their child’s existing health management plan before initiation.
Next Steps and Future Monitoring
Following this clearance, Dexcom Inc. is expected to integrate the pediatric indication into its broader product rollout. Regulatory monitoring of the device’s performance in the real-world pediatric environment will continue through the FDA’s post-market surveillance programs, which track reports of adverse events or performance issues.
Patients and caregivers can access official safety guidance and device specifications through the FDA’s medical device database. As this technology becomes available, I encourage parents to discuss the potential benefits and limitations of continuous glucose monitoring during their next scheduled pediatric check-up. We welcome your thoughts on how digital health tools are shaping your family’s approach to wellness; please share your perspectives in the comments section below.
Keep reading